Novira Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference In San Francisco

DOYLESTOWN, Pa., Jan. 9, 2015 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held, clinical stage, biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that Christian S. Schade, chief executive officer, is scheduled to present a company update and overview at the 33rd Annual J.P. Morgan Healthcare Conference at 11:30a.m. PT on Tuesday, January 13, 2015 at the Westin St. Francis Hotel in San Francisco, CA.

About NVR 3-778

NVR 3-778 is a small molecule, direct acting antiviral, for oral administration in patients with Chronic Hepatitis B (CHB) that inhibits the HBV core or capsid protein. HBV core is a novel and promising drug target with multiple activities required for viral replication and persistence. Inhibition of HBV core protein function by NVR 3-778 offers the potential for more efficient suppression of the virus leading to improved durable viral suppression and functional cure rates.

About HBV

Hepatitis B infection presents a significant unmet medical need with an estimated 350 million people worldwide living with chronic HBV infection. A significant number of patients with chronic infection incur a higher risk of developing cirrhosis and cancer. It is estimated that 60% of hepatocellular carcinoma (liver cancer) is a direct consequence of HBV infection. Current drugs approved for the management of CHB include PEG-Interferon and nucleot(s)ides which can effectively suppress virus replication, but rarely lead to a cure.

About Novira Therapeutics

Novira Therapeutics, Inc., is a privately held biopharmaceutical company focused on discovery and development of first-in-class antiviral drugs for the treatment of chronic HBV infection (CHB), a global disease with a high level of unmet medical need. The company is employing innovative chemistry and biology technologies to discover small molecule inhibitors of the HBV core or capsid protein as well as other drugs with novel mode of action. The company's novel antivirals will offer the potential to address the limitations of current CHB therapies when used either as mono-therapy or in combination with existing standards of care.

For more information, visit

The Novira Therapeutics name and logo are trademarks of Novira Therapeutics, Inc. or its affiliates.  All other trademarks referenced herein are owned by their respective owners.


Corporate Contact
Christian S. Schade
Chief Executive Officer

Media Contacts
David Schull
Matt Middleman, M.D.
Russo Partners
T: (212) 845-4271
T: (212) 845-4272

To view the original version on PR Newswire, visit:

SOURCE Novira Therapeutics, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news